Abstract-Stroke is the second single highest cause of death in Europe. The low reliability of animal models in replicating the human disease is one of the most serious problems in the field of medical and pharmaceutical research about stroke. The standard models for the study of ischemic stroke are often poorly predictive as they simulate only partially the human disease. This work aims at investigating animal models with diseases typically associated with the onset of stroke in human patients. We have designed and realised a knowledge base for collecting, elaborating, and extracting analytical results of genomic, proteomic, biochemical, morphological investigations from animal models of cerebral stroke. Data analysis techniques are tailored to make the data available for processing and correlation, in order to increase the predictive value of the preclinical data, to perform biosimulation studies, and to support both academic and industrial research in the area of cerebral stroke therapy. A first statistical analysis of the retrieved information leads to the validation of our animal models and suggests a predictive and translational value for parameters related to a specific model. In particular, concerning gene expression data, we have applied a data analysis pipeline that initially takes into account an initial set of 64,000 genes and brings down the focus on a few tens of them.
I. INTRODUCTION
Stroke is the second single highest cause of death in Europe [1] and more in general in the developed countries, the third in UK, and the fourth in the US. Up to 80 percent of strokes could be prevented. The low reliability of animal models in replicating the human disease is one of the most serious problems in the field of medical and pharmaceutical research about stroke. The standard models for the study of ischemic stroke are often poorly predictive as they simulate only partially the human disease. This work aims at investigating animal models with diseases typically associated with the onset of stroke in human patients. The purpose of this study is the evaluation of the evolution of different data types (with a special focus on gene expression data) among several strains of rats subject to different treatments that stimulate stroke, and some possible stroke consequences. This study is mainly intended to assess whether these new animal models are more consistent and predictive of the human condition. This increased knowledge could also reduce the number of animals used in these kinds of experimentations.
We have designed and realised a knowledge base (a data base) for collecting, elaborating, and extracting analytical results of genomic, proteomic, biochemical, morphological investigations from animal models of cerebral stroke. Data analysis techniques are tailored to make the data available for processing and correlation, in order to increase the predictive value of the preclinical data, to perform biosimulation studies, and to support research in the area of cerebral stroke therapy. A first statistical analysis of the retrieved information leads to the validation of our animal models and suggests a predictive and translational value for parameters related to a specific model. In particular, concerning gene expression data, we have applied a data analysis pipeline that initially takes into account an initial set of 64,000 genes and brings down the focus on a few tens of them. This paper is organised as follows. Section II introduces the data used (strains and treatments), the group models obtained for the comparative analysis, and the data types acquired for each group. Section III describes the method applied for the data collection and information retrieval, and the data analysis method for the gene expression data type, whose results are the focus of this paper. Section IV describes the results of such analysis and, finally, Section V concludes the paper.
II. DATA AND MODELS
The animal models were obtained with techniques of transient or permanent occlusion of the middle cerebral arteries, adapted for different types of animal groups.
A. Data
Three different strains of rat have been used for this preclinical study: Sham surgery is a faked operation where the control groups have received the same surgical procedure as the others, but without the occlusion procedure that induces ischemia. This allows to distinguish scientific data that reflect the effects of the experiment itself from that which is a consequence of the surgery. The transient occlusion consists in applying an occlusion in the middle cerebral arteries within a surgery, and then remove it after two hours, while the permanent occlusion is never removed. The distinction of these two treatments is meant to investigate the effects of reperfusion. Indeed, the blood supply after lack of oxygen can severely damage tissues ( [2] ) and can actually cause more damage than the actual ischemic event.
Finally, the data we aim to collect for our preclinical study is the following:
• Haematological data
• Blood chemistry data
• Gene expression data (MicroArray Analysis, NGS miRNA)
• Physiological data (body/organs weight and blood pressure)
• Enzyme activity data
• Histological data (optical microscopy)
• Receptor Binding data
• Neurological data (through behavioural observation and scores)
• Protein expression data (matrix expression)
• Mitochondrial damage data (SEM: Scanning Electron Microscopy)
• Proteomics data (Ms spectrometry, 2D electrophoresis)
B. The model
In Section II-A we described the strains and their possible treatments. This led to the following groups for our preclinical analysis:
SDS
Sham operated SD. SDP SD with Permanent occlusion. ZLS Sham operated ZL. ZLT ZL with Transient occlusion. ZDFS Sham operated ZDF. ZDFT ZDF with Transient occlusion.
As explained above, the sham-operated groups SDS, ZLS, and ZDFS are the control groups. All the others are those on which either transient or permanent ischemia is investigated. In the preclinical model, the ZDF strain has been chosen to test the effect of the treatments on animals that simulate the conditions of patients that are at high risk for ischemia. Unfortunately, no data could be collected for permanent occlusion of this group as ZDF rats did not survive the treatment, and this is why there is no ZDFP group. For the same reason, we did not perform permanent occlusion treatment on ZL strain, and hence we do not have a ZLP group, because the latter would have served as a control group for the missing ZDFP. In fact, we collected data to investigate permanent occlusion only for SD strain. 
A. Data Base and Information retrieval
As we have seen in last section, data exhibits strong heterogeneity. Moreover, the genomic, proteomic, biochemical and morphological investigations provide information of different multiplicity and with different number of attributes. We have designed and realised a knowledge base that collects all this data types (and that can also host possible new kind of data) in an updated, detailed and non-redundant way. The chosen DBMS software is PostgreSQL, and the script language used for reading and inserting data is python. SQL allows to extract data for each performed analysis, or aggregated data for type of analysis or group or specimen, and combinations. The database, by means of logical views to integrate information, can directly export data to the analysis workflow even for the kind of results with multiple answers per sample (microarrays, MALDI MS/MS, NGS). 
B. Data Analysis
In this section we show a data analysis we performed on the specific data type of gene expression.
For high-throughput data analysis we used methods from R-Bioconductor project ( [3] ), namely:
• limma: differential gene expression analysis for microarray data based on linear models and moderated T-statistics ( [4] , [13] , [6] ).
• EdgeR and DeSeq: differential expression analysis for count data based on negative binomial distribution ( [8] , [9] , [5] ).
For the Microarray analysis of the transcriptome, the following workflow was performed:
• Microarray scansion with Agilent one-color SurePrint G3 Rat GE 8x60K Microarray Kit.
• The generated raw data (a 64K records matrix per sample) were collected with Feature Extraction Software (Agilent proprietary software). The blue (right) circle represents the set of genes differentially expressed in the two condition (Sham and treatment) for the SD Strain, while the grey (left) circle is that of the ZL strain in its two conditions. Numbers (and circles' size) highlight the number of elements in the intersection and in the sets differences .
• Array quality was monitored using Agilent Feature Extraction Software QC Report to evaluate Microarray Performance for every sample. Samples whose QC report did not pass the quality control threshold were excluded.
• Data from all samples was merged into a single gene expression matrix collecting all samples that survived previous steps. Each single group now corresponds to a set of (contiguous) columns of this new matrix.
• Probes filtering: control probes and too low expressed genes were removed.
• Normalization was performed with quantile normalization between single groups arrays.
• Differential expression analyses were performed using two different techniques:
• Empirical Bayes-moderated F-statistics with the limma Bioconductor package.
• 1 way Anova with SNK post hoc test with the GeneSpring Agilent software.
• The two statistics gave comparable results. limma has been choosen to perform further analysis.
• Limma multi-group analysis has been performed on data. We obtained lists of differently expressed genes using threshold parameters: P − adjusted < 0.01/0.05 and F oldChange > 2.
• Unsupervised analysis (clustering) with different algorithms was performed on differentially expressed (DE) genes, to see if genes differently expressed for one contrast were giving good clustering also for other classes. Clustering was performed by Amic@ server, with K-means method and Pearson Correlation Coefficient ( [11] , [10] ).
As a result of such workflow, for each group up-regulated and low-regulated genes are highlighted and analysed. Section IV will show comparisons and clustering results with such data. 
SDP-SDS
ZDFT-ZDFS Fig. 3 . The right circle represents the set of genes differentially expressed in the two condition (Sham and treatment) for the ZDF Strain, while the left circle is that of the SD strain in its two conditions.
IV. RESULTS
Since our purpose is to investigate how the different strains reacted to the treatments, we first took into account the three pairs for comparison that are the three Sham operated groups against their treated ones: SDP-SDS, ZLT-ZLS, ZDFT-ZDFS (that is, the blu arrows of Fig. 1 ). The set of differentially expressed (DE) genes was filtered out for each such pair of groups. This resulted already in a quite strong reduction of the research space, because for all pairs the outcome was around few hundreds of genes out of the over 60,000 initial ones (see Figures 2,3,4) .
Then, differentially expressed genes resulting from such comparisons were compared between themselves showing a relevant intersection for the set of evolved genes in different strains. Figure 2 shows the Venn Diagram summarizing results for the pairs ZLT-ZLS against SDP-SDS. There are 476 differentially expressed genes for ZL in the two conditions (Sham and treated), and 464 for SD. As we can see, the intersection between these two sets is very significant. Similarly, Figure 3 shows the set of DE genes in the two conditions for the strains SD and ZDF, and again the intersection is relevant. Finally, Figure 4 shows the sizes and intersection for the DE genes of the strains ZL and ZDF, with the same result of large intersection.
We recall that in all cases the set of differentially expressed genes was extracted using two different techniques (Empirical Bayes-moderated F-statistics with the limma Bioconductor package, and 1 way Anova SNK post hoc test with the GeneSpring Agilent software), and that the results were in both cases this high amount of intersections. We believe that this is a good validation of our model, and an interesting practical result as it allows to bring down the focus from 64,000 genes to a few hundred that, on their turn, can be grouped into very few functional clusters.
To see whether these differences are due to the combination strain/treatments or only to strains we performed also the comparisons: SDS-ZLS, SDS-ZDFS, and ZLS-ZDFS that cross differentially expressed genes data for different strains. Results are shown in Figures 5, 6 , and 7. Also in this case, results show a significant intersection, and the combination of these and the previous return can drive a more accurate downstream analysis that will follow this work with a focus on the actual set of genes whose differential expression possibly results a significant preclinical result.
Indeed, as a final step, we performed a Gene Ontology analysis, a Functional Clustering analysis, and Pathway analysis on gene lists using, again, different tools and algorithms. We mainly used results from DAVID tools ( [12] , [17] ), and in For example, the Functional Annotation Clustering on ZLT-ZLS and on ZDFT-ZDFS differentially expressed genes show the major Enrichment Score for three biological processes: response to wounding, inflammatory response, defense response ( Figure 8 ). These results are not surprising and match the literature concerning the transcriptome gene expression observed in stroke injury. We consider this a validation of our model and of our workflow and results concerning the microarray data analysis. Nevertheless, both the gene expression data itself, and the whole model involving the types of data other than microarray that we collectedt, will be object of future investigations.
V. CONCLUSIONS
A first statistical analysis of the data showed different results for the various models, which appear to respond differently to similar treatments. In particular, the analysis of gene expression data showed how the model chosen for conditions that in human being are associated with higher risk for stroke, actually respond differently from other models when subjected to similar treatments. The use of new kinds of animal models can lead to new results in studies related to cerebral ischemia. Further and more detailed analysis of the database will indicate whether this approach allows a better match between the animal model and human pathological condition. 
